Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
AI Application in Anti-Money Laundering for Sustainable and Transparent Financial Systems
arXiv:2512.06240v1 Announce Type: new Abstract: Money laundering and financial fraud remain major threats to global financial stability, costing trillions annually and challenging regulatory oversight. This paper reviews how artificial intelligence (AI) applications can modernize Anti-Money Laundering (AML) workflows by improving detection accuracy, lowering false-positive rates, and reducing the operational burden of manual investigations, thereby supporting more sustainable development. It fu
-
Omics In Lung
-
Treatment of advanced-stage non-small cell lung cancer: Current progress and a glimpse into the future (Review)
Mol Clin Oncol. 2025 Mar 12;22(5):42. doi: 10.3892/mco.2025.2837. eCollection 2025 May.ABSTRACTBefore the twentieth century, patients with advanced lung cancer had limited treatment options and chemotherapy was the primary form of treatment, with an overall survival often <0.5 years. However, with advances in society and medical technology, the treatment approaches for advanced non-small cell lung cancer (NSCLC) have markedly changed. Traditional chemotherapy has been gradually replaced by ta
Treatment of advanced-stage non-small cell lung cancer: Current progress and a glimpse into the future (Review)
Mol Clin Oncol. 2025 Mar 12;22(5):42. doi: 10.3892/mco.2025.2837. eCollection 2025 May.
ABSTRACT
Before the twentieth century, patients with advanced lung cancer had limited treatment options and chemotherapy was the primary form of treatment, with an overall survival often <0.5 years. However, with advances in society and medical technology, the treatment approaches for advanced non-small cell lung cancer (NSCLC) have markedly changed. Traditional chemotherapy has been gradually replaced by targeted therapy and immunotherapy, leading to the emergence of various new therapeutic options that offer patients more personalized and precise care. This raises the question of what the future holds for the treatment of NSCLC. This review provides a comprehensive analysis of the latest breakthroughs in targeted therapies, immunotherapies, and drugs for antibody-drug conjugates (ADCs), highlights advances in multimodal combination therapy strategies, and explores the causes of resistance and the challenges that exist in overcoming it. In particular, this review provides unique insights into key directions for future research in NSCLC, such as personalised treatment strategies and biomarker exploration based on multi-omics data, aiming to provide new inspiration for clinical decision-making and research.
PMID:40160297 | PMC:PMC11948471 | DOI:10.3892/mco.2025.2837